Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

Fosun Pharma Given OK for Hong Kong IPO

publication date: Apr 11, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Shanghai Fosun Pharma has been given regulatory approval to issue 547 million H shares in a Hong Kong IPO. The transaction is expected to occur in the second quarter. Because the company's Shanghai stock price has slipped lower in the last six months, the offering has also dropped in size from the original announcement: it is now expected in a range between $600 million and $800 million, down from an initial $960 million. More details....

Stock Symbol:  (SHA: 600196)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2013
  May 29-30, 2013
Beijing, China

>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners